Abstract Details

Title Quantitative MRI Biomarkers of Neurodegenerative Diseases: Moving from Scientific Insights toward Clinical Practice

Topic Aging and Dementia

Presentation(s) P06 - (-)

Poster/Presentation
Number 030

Objective

Background BACKGROUND: Patients with Alzheimer's disease, Frontotemporal Dementia, Posterior Cortical Atrophy, and other neurodegenerative diseases may present diagnostic challenges to the neurologist, especially early in their course or in atypical cases. Although a brain MRI scan is usually obtained in the evaluation of patients suspected of having these conditions, at present most clinical practices visually inspect these scans but do not routinely perform quantitative analyses to try to identify abnormalities of brain structure.

Design/Methods DESIGN/METHODS: Employing publicly available software (FreeSurfer), we developed a method to apply this suite of software tools to MRI scans obtained in our clinical practice and produce quantitative reports of brain structure readable by clinicians, producing Z scores across the cerebral cortex and for specific subcortical brain structures which are used to identify abnormalities. We then compare the spatial patterns of abnormal brain structure to "disease signature" patterns from groups of individuals with neurodegenerative diseases.

Results RESULTS: In many patients, the quantitative maps of cortical atrophy and other abnormalities in brain structure are consistent with known patterns of one of the neurodegenerative diseases. In some cases, abnormalities were subtle enough that they were not confidently identified from visual inspection of MRI scans but were readily detectable from quantitative analysis.

Conclusions CONCLUSIONS: Our findings underscore the potential value of quantitative analysis of MRI scans in clinical practice as part of the diagnostic evaluation of patients with neurodegenerative diseases. Further work is in progress to compare these findings with FDG-PET and to analyze MRI scans from patients with molecular markers of neuropathology.

Authors/Disclosures
Bradford Dickerson, MD, FAAN PRESENTER	Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lantheus. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Dickerson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Dickerson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Dickerson has received publishing royalties from a publication relating to health care. Dr. Dickerson has received publishing royalties from a publication relating to health care.
Kimiko Domoto-Reilly, MD	Dr. Domoto-Reilly has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MedBridge. The institution of Dr. Domoto-Reilly has received research support from Lawson Health Research Institute. The institution of Dr. Domoto-Reilly has received research support from NIH. The institution of Dr. Domoto-Reilly has received research support from Biogen. The institution of Dr. Domoto-Reilly has received research support from Lewy Body Dementia Association. The institution of Dr. Domoto-Reilly has received research support from Garvey Institute for Brain Health Solutions. The institution of Dr. Domoto-Reilly has received research support from Cognition Therapeutics. The institution of Dr. Domoto-Reilly has received research support from Takayama Family.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Stefan M. Pulst, MD, FAAN (University of Utah)	Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for venrock. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leverna. Dr. Pulst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Pulst has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Leninthal LLC. The institution of Dr. Pulst has received research support from NINDS. Dr. Pulst has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��